Antiproliferative drugs used to treat patients with advanced systemic mastocytosis
| Drug . | Effects seen in SSM and slowly progressing ASM . | Effects seen in ASM or MCL with rapid progression . |
|---|---|---|
| Interferon-α | Responses including MR in a group of patients | Usually no responses seen |
| 2CdA | Responses frequently seen; MR in a group of patients | Transient responses in a few patients |
| PKC412 | Studies ongoing | Studies ongoing and transient responses in some cases23 |
| Dasatinib | Studies ongoing | Studies ongoing |
| Polychemotherapy | — | May induce remission or debulking before SCT |
| Experimental drugs | ||
| mTOR blockers | Studies ongoing | Studies ongoing |
| PI3 kinase blockers | Studies planned | Studies planned |
| Drug . | Effects seen in SSM and slowly progressing ASM . | Effects seen in ASM or MCL with rapid progression . |
|---|---|---|
| Interferon-α | Responses including MR in a group of patients | Usually no responses seen |
| 2CdA | Responses frequently seen; MR in a group of patients | Transient responses in a few patients |
| PKC412 | Studies ongoing | Studies ongoing and transient responses in some cases23 |
| Dasatinib | Studies ongoing | Studies ongoing |
| Polychemotherapy | — | May induce remission or debulking before SCT |
| Experimental drugs | ||
| mTOR blockers | Studies ongoing | Studies ongoing |
| PI3 kinase blockers | Studies planned | Studies planned |
All antiproliferative drugs used are experimental in nature.
MR indicates major clinical response; —, not applicable; mTOR, mammalian target of rapamycin; and PI3, phosphatidylinositol 3.